Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.

Humans Lurasidone Hydrochloride / adverse effects Schizophrenia / drug therapy Serotonin Isoindoles / pharmacology Thiazoles / pharmacology Antipsychotic Agents / adverse effects Weight Gain
antipsychotics lurasidone schizophrenia serotonin-dopamine antagonist

Journal

Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745

Informations de publication

Date de publication:
2023
Historique:
received: 07 07 2023
accepted: 15 09 2023
medline: 5 10 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: epublish

Résumé

This review aims to provide a comprehensive overview of the current literature on the drug design, development, and therapy of lurasidone for the treatment of schizophrenia. Lurasidone has antagonistic effects on the dopamine D

Identifiants

DOI: 10.2147/DDDT.S366769 PMID: 37789971 PMC: PMC10544203
pubmed: 37789971
doi: 10.2147/DDDT.S366769
pii: 366769
pmc: PMC10544203
doi:

Substances chimiques

Lurasidone Hydrochloride O0P4I5851I
Serotonin 333DO1RDJY
Isoindoles 0
Thiazoles 0
Antipsychotic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3023-3031

Informations de copyright

© 2023 Miura et al.

Déclaration de conflit d'intérêts

Dr. Miura has received speaker’s honoraria from Sumitomo, Eisai, Janssen, Meiji Seika Pharma, Otsuka, Takeda, Towa, Tanabe-Mitsubishi, and Yoshitomi. Dr. Horikoshi has received honoraria for lectures from Sumitomo, Janssen, Meiji Seika Pharma, Otsuka, Takeda, Lundbeck, and Yoshitomi. Drs. Ichinose, Suzuki, and Watanabe declare no conflicts of interest in this work.

Références

Behav Brain Res. 2013 May 1;244:66-9
pubmed: 23376699
Expert Opin Pharmacother. 2022 Nov;23(16):1801-1818
pubmed: 36398838
Neuroreport. 2012 May 9;23(7):436-40
pubmed: 22415605
Am J Psychiatry. 2011 Sep;168(9):957-67
pubmed: 21676992
J Clin Psychiatry. 2013 May;74(5):507-15
pubmed: 23541189
Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
pubmed: 15925493
Neuropharmacology. 2013 Jul;70:211-7
pubmed: 23416039
Int J Neuropsychopharmacol. 2021 Mar 17;24(3):200-215
pubmed: 33151310
Schizophr Res Cogn. 2016 Jun 02;5:7-12
pubmed: 28740811
Eur Child Adolesc Psychiatry. 2020 Sep;29(9):1195-1205
pubmed: 31758359
Brain Sci. 2023 Mar 04;13(3):
pubmed: 36979255
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Front Psychiatry. 2022 Jun 06;13:917351
pubmed: 35733796
World Psychiatry. 2013 Oct;12(3):216-26
pubmed: 24096780
Clin Pharmacokinet. 2017 May;56(5):493-503
pubmed: 27722855
Neuropsychiatr Dis Treat. 2021 Jan 20;17:125-137
pubmed: 33505160
Am J Psychiatry. 2020 Apr 1;177(4):342-353
pubmed: 31838873
Schizophr Res. 2022 Feb;240:205-213
pubmed: 35032906
J Psychiatr Res. 2018 Aug;103:244-251
pubmed: 29906709
Neuropsychopharmacology. 2012 Sep;37(10):2175-83
pubmed: 22739469
Int J Neuropsychopharmacol. 2013 Jul;16(6):1205-18
pubmed: 23199972
Lancet Psychiatry. 2017 Apr;4(4):295-301
pubmed: 28237639
Int J Mol Sci. 2018 Oct 10;19(10):
pubmed: 30309037
Schizophr Res. 2015 Aug;166(1-3):334-8
pubmed: 26117157
Behav Brain Res. 2010 May 1;209(1):99-108
pubmed: 20097233
Int J Neuropsychopharmacol. 2014 Oct 31;18(4):
pubmed: 25522402
Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82
pubmed: 24035633
CNS Drugs. 2019 Jun;33(6):549-566
pubmed: 31065941
J Psychopharmacol. 2016 Jan;30(1):69-77
pubmed: 26645209
BMC Psychiatry. 2020 May 5;20(1):199
pubmed: 32370778
Lancet Psychiatry. 2022 Aug;9(8):614-624
pubmed: 35753323
Expert Opin Investig Drugs. 2009 Nov;18(11):1715-26
pubmed: 19780705
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Behav Brain Res. 2011 Jun 20;220(1):83-90
pubmed: 21277905
Acta Psychiatr Scand Suppl. 1994;384:116-24
pubmed: 7879633
Epidemiol Psychiatr Sci. 2019 Jun 07;29:e39
pubmed: 31172899
J Neurochem. 2014 Mar;128(6):938-49
pubmed: 24164459
Psychiatry Clin Neurosci. 2020 Jun;74(6):336-343
pubmed: 31823444
J Pharmacol Exp Ther. 2010 Jul;334(1):171-81
pubmed: 20404009
J Psychopharmacol. 2020 Apr;34(4):420-428
pubmed: 31913065
Int J Neuropsychopharmacol. 2012 Mar;15(2):235-46
pubmed: 21349227
Ann Gen Psychiatry. 2022 Dec 16;21(1):49
pubmed: 36527022
Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250
pubmed: 34025981
J Clin Psychopharmacol. 2017 Apr;37(2):138-147
pubmed: 28141623
J Clin Psychopharmacol. 2023 Mar-Apr 01;43(2):157-160
pubmed: 36825872
Int Clin Psychopharmacol. 2012 May;27(3):165-76
pubmed: 22395527
J Clin Psychopharmacol. 2020 May-Jun;40(3):240-249
pubmed: 32332459
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
J Pharmacol Exp Ther. 2011 Aug;338(2):605-14
pubmed: 21558435

Auteurs

Itaru Miura (I)

Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
ORCID: 0000-0002-2133-5809

Sho Horikoshi (S)

Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Department of Neuropsychiatry, Horikoshi Psychosomatic Clinic, Fukushima, Japan.

Mizue Ichinose (M)

Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Department of Neuropsychiatry, Hoshigaoka Hospital, Koriyama, Japan.

Yuhei Suzuki (Y)

Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.

Kenya Watanabe (K)

Department of Pharmacy, Fukushima Medical University Hospital, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Chlorhydrate de lurasidone › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Schizophrénie › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Sérotonine › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › Lurasidone for the Treatment of Schizophrenia:...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Mensurations corporelles › Poids › Modifications du poids corporel › Prise de poids › Lurasidone for the Treatment of Schizophrenia:...